66192-05-0

Upstream product

• 174265-12-4 2-bromo-5-chlorobenzaldehyde 
• 2033-24-1 cycl-isopropylidene malonate 
• 66192-18-5 2-(2-Bromo-5-chloro-benzyl)-malonic acid diethyl ester 

Downstream Products

• 947616-94-6 C₁₃H₁₅BrClNO 
• 1624332-61-1 methyl 3-(2-(benzo[d][1,3]dioxol-5-yl)-5-chlorophenyl)propanoate 
• 1624332-78-0 3-(2-(benzo[d][1,3]dioxol-5-yl)-5-chlorophenyl)propanal 
• 1624332-43-9 5-(2-(but-3-yn-1-yl)-4-chlorophenyl)benzo[d][1,3]dioxole 
• 66191-93-3 methyl 3-(2-bromo-5-chlorophenyl)propanoate 
• 1161440-69-2 3-(2-bromo-5-chloro-phenyl)propan-1-ol 

Relevant academic research and scientific papers

Highly efficient gold-catalyzed synthesis of dibenzocycloheptatrienes

Dibenzocycloheptatrienes are obtained by a gold-catalyzed 7-exo-dig hydroarylation protocol in a highly efficient manner. The gold-catalyzed reaction usually gives the products in high yields and excellent selectivity. This procedure provides an easy and

Phenylpiperidine derivatives as melanocortin-4 receptor modulators

The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators

The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally, all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.